Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
CC-94676-PCA-001
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT04428788 ↗
- Completed
- Celgene
- Focused
We haven't built an HCP commentary report on CC-94676-PCA-001 (BMS-986365 plus CC1083611 plus CC1083610 in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CC-94676-PCA-001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- CC-94676; CC1083611; CC1083610
- Arms
- Administration of CC-94676, CC1083611, and CC1083610 · Experimental
- Enrollment
- 131
- Primary outcomes
- Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria
- Dose-limiting toxicity (DLT)
- Non-tolerated dose (NTD)
- Maximum tolerated dose (MTD)
- Sponsor
- Celgene
- Start
- Jun 22, 2020
- Primary completion
- Oct 28, 2025
- Results posted
- No
- Registry record
- NCT04428788 · updated Dec 22, 2025
Publications
linked from the registry- Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16. PubMed 39293515